Pipeline
EU101
| Indication Solid tumor | Target /Drug class Anti-human 4-1BB mAb | Development Stage Phase I/II study |
Summary
- Anti-human 4-1BB monoclonal therapeutic antibody
- Better efficacy for tumor clearance than competitors in vivo
- Accelerates infiltration of lymphocyte into tumor tissue
- Promising platform technology for combination therapy with immune checkpoint inhibitors
